We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Sponsor content
215 result(s) found, displaying 51 to 60
-
Prescription medicine registrationActive ingredients: Brentuximab vedotin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVTENCITY maribavir 200 mg film coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 30 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 10 mg film-coated tablet bottle.
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Australian public assessment report (AusPar)AusPAR for Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies
-
Prescription medicine registrationActive ingredients: vedolizumab.
-
Australian public assessment report (AusPar)AusPAR for Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.
-
Designation or determinationOrphan drug
-
Prescription medicine decision summaryLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).